NDAORALCAPSULE
Approved
Oct 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
VIVLODEX (meloxicam) by Ascentage Pharma is cyclooxygenase inhibitors [moa]. Approved for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis. First approved in 2015.
Drug data last refreshed Yesterday
Mechanism of Action
Cyclooxygenase Inhibitors
Worked on VIVLODEX at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.